Orthofix Medical Inc. is a global medical technology company that develops and markets implantable medical devices, biologics, and enabling technologies for musculoskeletal pathologies. The company operates through two primary segments: Global Spine and Global Limb Reconstruction. Its product portfolio includes spinal hardware, bone growth therapies, limb reconstruction systems, and the 7D FLASH Navigation System. Orthofix serves hospitals, ambulatory surgery centers, and outpatient facilities worldwide, with a significant presence in the United States for its bone growth stimulation devices. The company utilizes pulsed electromagnetic field and low intensity pulsed ultrasound technologies for non-invasive bone healing. It collaborates with clinical organizations such as MTF Biologics and Texas Scottish Rite Hospital for Children for research and development. Founded in 1980 in Verona, Italy, the company was formerly known as Orthofix International N.V. before changing its name and jurisdiction in 2018. In January 2023, Orthofix completed a merger of equals with SeaSpine Holdings Corporation, integrating SeaSpine’s assets into its global spine business.

Summarised from the company's own disclosures, fiscal year ended Feb 2026

Industry Medical Devices Homepage orthofix.com
Sector Healthcare IR page ir.orthofix.com/overview/default.aspx
Tags
spinal implants, bone growth therapies, limb reconstruction, biologics, surgical navigation, pulsed electromagnetic field, low intensity pulsed ultrasound, orthopedic hardware, bone graft substitutes, musculoskeletal care, 7D FLASH Navigation System, CervicalStim, SpinalStim, PhysioStim, AccelStim, MTF Biologics, SeaSpine, Orthofix Therapeutic Solutions
Press page —

Metrics

Valuation  
Market cap $ 286.881M
Market cap (USD) $ 286.881M
P/E -6.34
PEG —
P/BV 0.67
P/S 0.34
P/OCF 67.88
P/FCF -6.45
Dividend yield —
Turnover / mcap —
Returns  
ROE -19.3%
ROI -15.2%
ROIC -10.1%
Profit margin -11.2%
Growth  
Revenue growing Yes
Profits growing Yes
Revenue up 3y Yes
Revenue up 5y No
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding Yes
Buying back stock No
Diluting (TTM) Yes
Debt/Equity 51.6%
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 6
Quality score -23.5%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010 FY 2009 FY 2008 FY 2007 FY 2006 FY 2005 FY 2004 FY 2003 FY 2002 FY 2001
Revenue 822.312M 799.491M 746.641M 460.713M 464.479M 406.562M 459.955M 453.042M 433.823M 409.788M 396.489M 402.277M 400.534M 462.32M 578.988M 564.37M 545.635M 519.675M 490.323M 365.359M 313.304M 286.638M 203.707M 177.595M 162.36M
Net profit -92.192M -125.997M -151.395M -19.749M -38.379M 2.517M -28.462M 13.811M 6.223M 3.056M -2.809M -8.537M -25.515M 51.295M -1.073M 44.208M 24.472M -228.554M 10.968M -7.042M 73.402M 34.149M 24.73M 25.913M 20.964M
Free cash flow -1.279M -9.086M -106.009M -32.902M 690K 58.787M 13.036M 36.326M 38.676M 28.275M 16.027M 32.889M 42.094M -16.788M 39.816M 16.664M 29.055M 11.17M — — — 15.242M 26.551M 22.174M 12.099M

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010 FY 2009 FY 2008 FY 2007 FY 2006 FY 2005 FY 2004 FY 2003 FY 2002 FY 2001
Share price 14.21 17.14 13.47 — 31.15 37.41 42.28 61.63 52.08 36.84 42 33.25 26.52 41.4 34.25 26.73 10.94 10.94 57.1 50 37.78 — — — —
Price performance 12m -0.17 0.27 — — -0.17 -0.12 -0.31 0.18 0.41 -0.12 0.26 0.25 -0.36 0.21 0.28 1.44 0 -0.81 0.14 0.32 — — — — —

Filed figures

Figure Dec 2016 Dec 2017 Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (USD) 57.8M 63.4M 77.7M 86.8M 72.4M 78.6M 82.9M 128M 135M 136M
↳ YoY growth -3.3% +9.7% +22.6% +11.7% -16.6% +8.5% +5.5% +54.6% +5.2% +0.8%
↳ 5y CAGR -17.0% -15.8% +0.6% +7.2% +3.9% +6.3% +5.5% +10.5% +9.2% +13.4%
Borrowings, current (USD) — — — — — — — 1.25M 0.00 0.00
Borrowings, non-current (USD) — — — — — — — 93.1M 157M 157M
Lease liabilities (USD) — — 20.5M 26.9M 27.9M 25.8M 26.9M 39.8M 36.7M 46.5M
Cash and deposits (USD) 39.6M 81.2M 69.6M 69.7M 96.3M 87.8M 50.7M 33.1M 83.2M 82M
Intangible assets (USD) 7.46M 10.5M 51.9M 54.1M 60.5M 52.7M 47.4M 117M 98.8M 72.8M
Right-of-use assets (USD) — — 20.2M 5.8M 4.84M 3.16M 6.79M 19.9M 17.2M 22.3M
Net debt (borrowings + leases - cash) (USD) — — — — — — — 101M 110M 122M
Cash flow detail
Operating cash flow (USD) 44.7M 53.3M 49.9M 32M 74.3M 18.5M -11.5M -45.8M 25.8M 33.3M
Purchases of property, plant and equipment (USD) -16.4M -14.7M -13.6M -19M -15.5M -17.8M -21.4M -60.3M -34.9M -34.6M
Purchases of intangible assets (USD) -1.9M -2.28M -1.66M -1.53M -1.61M -1.81M -1.8M -1.79M — —
Change in receivables (cash effect) (USD) 392,000 -6.56M -3.71M -11M 13.3M -7.05M -6.74M -10.4M -9.53M -1.58M
Change in inventories (cash effect) (USD) -5.28M -15.6M 9.7M -5.71M -873,000 619,000 -18.1M -58.1M -5.55M -10.7M
Change in payables (cash effect) (USD) -1.77M 2.32M -170,000 2.14M 2.53M 4.25M 2.28M 8.64M -5.57M 2.6M
Share buybacks (cash effect) (USD) -63.4M — — — — — — — — —
Interest paid (cash effect) (USD) -672,000 -811,000 -800,000 -800,000 -1.9M -1.5M -1.4M -5.8M -16.9M -17.3M
Income taxes paid (cash effect) (USD) -4.42M -3.27M -15.6M -8.1M -500,000 -4.8M — -880,000 -1.3M -1.58M
Share-based compensation (USD) 16M 12.6M 18.9M 21.5M 16.2M 15.4M 18.4M 35.7M 32.5M 28.7M
Operating cash flow before change in receivables (USD) 44.3M 59.9M 53.6M 43.1M 61M 25.5M -4.8M -35.3M 35.3M 34.9M
Free cash flow (OCF - PPE - intangibles) (USD) 26.4M 36.4M 34.7M 11.5M 57.2M -1.12M -34.7M -108M -9.09M -1.28M
Income detail
Research and development expense (USD) 28.8M 29.7M 33.2M 34.6M 39.1M 49.6M 49.1M 80.2M 73.6M 65.8M
↳ 5y CAGR +2.8% +0.8% +4.4% +6.7% +8.2% +11.5% +10.6% +19.3% +16.3% +11.0%
Total comprehensive income (USD) 2.71M 16.6M 13.3M -35.7M 8.81M -41.6M -21.1M -151M -129M -87.3M
Comprehensive income to owners (USD) 2.71M 16.6M 13.3M -35.7M 8.81M -41.6M -21.1M -151M -129M -87.3M
Provision for credit losses (USD) 1.12M 1.64M -599,000 1.89M 199,000 444,000 2.1M 820,000 2M 2.26M
Credit cost ratio (credit losses / average receivables) (%) 1.9% 2.7% 0.8% 2.3% 0.2% 0.6% 2.6% 0.8% 1.5% 1.7%
Reported Feb 26, 2018 Feb 26, 2018 Oct 28, 2019 Feb 24, 2020 Feb 26, 2021 Feb 25, 2022 Mar 6, 2023 Feb 24, 2026 Feb 24, 2026 Feb 24, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

LEWISVILLE, Texas — November 9, 2026 — Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today reported financial results for the third quarter ended September 30, 2026, and revised its full-year 2026 net sales and non-GAAP adjusted EBITDA guidance. Unless otherwise noted, pro forma results exclude the impact of the discontinued M6™ product lines.

Third Quarter 2026 Highlights

•Total reported net sales of $207.9 million, representing an increase of 1% on a reported basis and 2% on a pro forma constant currency basis compared with the prior year period.

•Reported net loss of $(6.1) million and non-GAAP adjusted EBITDA of $26.0 million.

•Revised full-year 2026 pro forma net sales guidance to $825 million to $830 million and non-GAAP adjusted EBITDA guidance to $86 million to $88 million, reflecting third-quarter performance and the anticipated fourth quarter impact of actions to improve U.S. Spine execution, instrument set availability and asset productivity.

•Global Spine Fixation1 net sales increased 1% on a reported and constant currency basis compared with the prior year period.

October 23, 2026

Company to Host Conference Call on Monday, November 9, 2026, at 8:30 am Eastern Time

LEWISVILLE, Texas--(BUSINESS WIRE)-- Orthofix Medical Inc . (NASDAQ:OFIX), a leading global medical technology company, today announced that it will release its third quarter 2026 financial results on Monday, November 9, 2026, before market open. The Company will host a conference call and webcast to review results at 8:30 am Eastern Time the same day.

Interested parties may access the conference call by dialing 833-461-5787 in the U.S., and 585-542-9983 in all other locations, and referencing the conference ID 165 515 415. A webcast of the conference call and a copy of the release may be accessed at ir.Orthofix.com.

Internet Posting of Information

Orthofix regularly shares important updates in the “Investors” section of its website at Orthofix.com . The Company encourages investors and potential investors to consult the Orthofix website regularly for important information about Orthofix.

About Orthofix

Orthofix is a global medical technology company dedicated to advancing healing and restoring mobility for patients with complex musculoskeletal conditions. Headquartered in Lewisville, Texas, the Company offers a differentiated portfolio of spinal implants, therapeutic solutions, limb reconstruction systems, biologics and enabling technologies, including the 7D FLASH™ Navigation System. Orthofix’s technology-enabled solutions are designed to support surgeons across the continuum of care and improve outcomes for patients. Learn more at Orthofix.com and follow Orthofix on LinkedIn .

Investors and Media
Julie Dewey, IRC
Chief Investor Relations & Communications Officer
[email protected]

+1 209.613.6945

Source: Orthofix Medical Inc.

View All News

Investor Email Alerts

Personal Information.

Email Address *Required Email Address is required. Email Address is invalid.

Investor Alert Options *

  • News
  • Quarterly Reports
  • Annual Reports
  • SEC Filings
  • End of Day Stock Quote
  • Events & Presentations

Investor Alert Options is required.

The captcha test has failed. Please try again.

Submit

Unsubscribe

IR Contact

Julie Dewey

[email protected]

[email protected]

Quick Links

Company Name, Logo

                               


The materials on this site are for your general educational information only. Information you read on this website cannot replace the relationship that you have with your healthcare professional. We do not practice medicine or provide medical services as a part of this website. You should always talk to your healthcare professional for diagnosis and treatment.

© 2026 Orthofix Medical Inc. - All rights reserved

Powered By Q4 Inc. 5.190.1.9 (opens in new window)

August 5, 2026

LEWISVILLE, Texas--(BUSINESS WIRE)-- Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today reported its financial results for the second quarter ended June 30, 2026, reflecting progress toward a more focused and consistent operating model. The Company also raised its full-year 2026 guidance for both net sales and adjusted EBITDA. All pro forma measures contained within this release exclude the impact of the discontinued M6™ product lines.

Highlights

  • Second quarter 2026 reported net sales of $210.9 million, representing an increase of 4% on a reported basis and 5% on a pro forma constant currency basis compared to second quarter 2025.
  • Generated double-digit constant currency growth in Global Spine Fixation1 and Global Limb Reconstruction, reflecting strong international performance and continued demand across key growth platforms.
  • Therapeutic Solutions (formerly Bone Growth Therapies) delivered 3% year-over-year net sales growth despite a temporary Medicare reimbursement headwind affecting bone growth stimulators during part of the second quarter.
  • Biologics stabilized and began to regain momentum, supported by focused commercial execution.
  • Second quarter 2026 reported net loss of $(15.8) million and non-GAAP adjusted EBITDA of $20.1 million.

“Our second quarter results provide further evidence that the operational actions we have taken over the past year are beginning to show up more clearly in the business,” said Massimo Calafiore, President and Chief Executive Officer of Orthofix. “We delivered 5% pro forma, constant-currency net sales growth, supported by double-digit growth in Global Limb Reconstruction and Spine Fixation, sequential momentum in Biologics, and the restoration of Medicare reimbursement for bone growth stimulators, which removes a meaningful headwind for our Therapeutic Solutions business as we enter the second half of the year.”

Mr. Calafiore continued, “While our transformation remains a work in progress, we believe Orthofix is operating from a stronger position than it was a year ago. Our focus remains on improving the quality of growth, strengthening commercial productivity, and building a more consistent path to profitability and cash generation. As we continue to execute with discipline, we believe we are building a stronger foundation for durable, profitable growth and long-term shareholder value.”

1 Spine Fixation is comprised of the Company’s Spinal Implants product category, excluding motion preservation product offerings.

Financial Results Overview

Second Quarter 2026 Net Sales and Financial Results

The following table provides net sales by major product category and by reporting segment on a pro forma basis, removing the effects of the Company’s discontinued M6 product lines:

Three Months Ended June 30,
(Unaudited, U.S. Dollars, in millions) 2026 2025 Change Constant Currency Change
Therapeutic Solutions $ 64.2 $ 62.6 2.5 % 2.5 %
Spinal Implants, Biologics and Enabling Technologies* 109.0 104.8 4.0 % 4.0 %
Global Spine* 173.2 167.4 3.5 % 3.5 %
Global Limb Reconstruction 37.7 33.3 13.2 % 11.0 %
Pro forma net sales* 210.9 200.7 5.1 % 4.7 %
Impact from discontinuation of M6 product lines 0.0 2.4 (97.4 %) (97.5 %)
Reported net sales $ 210.9 $ 203.1 3.8 % 3.5 %
* Results above for each of Spinal Implants, Biologics, and Enabling Technologies; Global Spine; and pro forma net sales exclude the impact from discontinuation of the M6 product lines. Since pro forma net sales represent a non-GAAP measure, see the reconciliation above of the Company’s pro forma net sales to its reported figures under U.S. GAAP. The Company’s reported figures under U.S. GAAP represent each of the pro forma line items discussed above plus the impact from discontinuation of the M6 product lines.

For the second quarter of 2026, net sales were $210.9 million, representing an increase of 3.8% on a reported basis and 4.7% on a non-GAAP pro forma constant currency basis compared to second quarter 2025.

For the second quarter of 2026, GAAP gross margins were 71.0% and were 71.7% on a non-GAAP adjusted basis.

For the second quarter of 2026, reported net loss was $(15.8) million, or $(0.39) per share compared to reported net loss of $(14.1) million, or $(0.36) per share in the prior year period. Non-GAAP adjusted EBITDA was $20.1 million, or 9.6% of pro forma net sales, in the second quarter of 2026, compared to non-GAAP adjusted EBITDA of $20.6 million, or 10.3% of pro forma net sales, in the second quarter of 2025.

Liquidity

Cash, cash equivalents, and restricted cash on June 30, 2026, totaled $104.4 million compared to $120.9 million on March 31, 2026. The decrease was due to arbitration award and settlement payments related to pending claims from three former executives terminated in 2023.

Business Outlook

Following the restoration of Medicare reimbursement for non-invasive bone growth stimulators to its prior level, second-quarter performance, and the Company’s current expectations for the remainder of the year, Orthofix is increasing its full-year 2026 guidance for both net sales and adjusted EBITDA. All measures are provided on a non-GAAP pro forma basis and are based on current foreign currency exchange rates.

  • Net sales are now expected to range from $845 million to $855 million, an increase of $7 million at both the low and high ends of the range from the Company’s previous guidance of $838 million to $848 million issued on May 21, 2026. The updated range represents approximately 5% year-over-year pro forma constant currency growth at the midpoint and does not take into account any additional exchange rate changes that may occur this year.
  • The Company is increasing its full-year 2026 non-GAAP adjusted EBITDA guidance to $95 million to $98 million, compared to its previous guidance of $90 million to $93 million issued on May 21, 2026. The updated range reflects continued operating discipline and cost management, while also balancing planned growth investments and geographic mix dynamics. At the midpoint, this represents 80 basis points of non-GAAP adjusted EBITDA margin expansion compared to 2025.

An investor presentation for the Company’s second quarter 2026 financial results is available in the “Events & Presentations” section of the Orthofix Investor Relations Website at ir.orthofix.com .

Conference Call

Orthofix will host a conference call today at 8:30 AM Eastern Time to discuss the Company’s financial results for the second quarter ended June 30, 2026. Interested parties may access the conference call by dialing (888) 596-4144 in the U.S., and (646) 968-2525 in all other locations, and referencing the conference ID 8700861. A webcast and replay of the conference call may be accessed in the “Events & Presentations” section of the Orthofix Investor Relations Website at ir.orthofix.com .

Internet Posting of Information

Orthofix regularly shares important updates in the “Investors” section of its website at www.orthofix.com . The Company encourages investors and potential investors to consult the Orthofix website regularly for important information about Orthofix.

About Orthofix

Orthofix is a global medical technology company dedicated to advancing healing and restoring mobility for patients with complex musculoskeletal conditions. Headquartered in Lewisville, Texas, the Company offers a differentiated portfolio of spinal implants, therapeutic solutions, limb reconstruction systems, biologics and enabling technologies, including the 7D FLASH™ Navigation System. Orthofix’s technology-enabled solutions are designed to support surgeons across the continuum of care and improve outcomes for patients. Learn more at Orthofix.com and follow Orthofix on LinkedIn .

Forward-Looking Statements

This communication contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended, relating to our business and financial outlook, which are based on our current beliefs, assumptions, intentions, plans, expectations, estimates, forecasts and projections. In some cases, you can identify forward-looking statements by terminology such as “may,” “will,” “should,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “projects,” “intends,” “predicts,” “potential,” “positioned,” “deliver,” or “continue” or other comparable terminology. Forward-looking statements in this communication include the Company’s expectations regarding net sales and adjusted EBITDA for the year ended December 31, 2026. Forward-looking statements are not guarantees of our future performance, are based on our current expectations and assumptions regarding our business, the economy and other future conditions, and are subject to risks, uncertainties and changes in circumstances that are difficult to predict, including the risks described in Part I, Item 1A under the heading Risk Factors in our Annual Report on Form 10-K for the year ended December 31, 2025, and in Part II, Item 1A under the heading Risk Factors in our Quarterly Report on Form 10-Q for the quarter ended June 30, 2026. Factors that could cause future results to differ from those expressed by forward-looking statements include, but are not limited to, (i) our ability to maintain operations to support our customers and patients in the near-term and to capitalize on future growth opportunities, (ii) risks associated with acceptance of surgical products and procedures by surgeons and hospitals, (iii) development and acceptance of new products or product enhancements, (iv) clinical and statistical verification of the benefits achieved via the use of our products, (v) our ability to adequately manage inventory, (vi) our ability to successfully optimize our commercial channels, (vii) our success in defending legal proceedings brought against us, and (viii) the other risks and uncertainties more fully described in our periodic filings with the Securities and Exchange Commission (the “SEC”). As a result of these various risks, our actual outcomes and results may differ materially from those expressed in these forward-looking statements.

Further, any forward-looking statement speaks only as of the date hereof, unless it is specifically otherwise stated to be made as of a different date. The Company undertakes no obligation to update, and expressly disclaims any duty to update, its forward-looking statements, whether as a result of circumstances or events that arise after the date hereof, new information, or otherwise, except as required by law.

The Company is unable to provide expectations of GAAP net income (loss), the closest comparable GAAP measures to adjusted EBITDA (which is a non-GAAP measure), on a forward-looking basis because the Company is unable to predict, without unreasonable efforts, the ultimate outcome of matters (including acquisition-related expenses, accounting fair value adjustments, and other such items) that will determine the quantitative amount of the items excluded in calculating adjusted EBITDA, which items are further described in the reconciliation tables and related descriptions below. These items are uncertain, depend on various factors, and could be material to the Company’s results computed in accordance with GAAP.

ORTHOFIX MEDICAL INC.Condensed Consolidated Statements of Operations
Three Months Ended Six Months Ended
June 30, June 30,
(Unaudited, U.S. Dollars, in thousands, except share and per share data) 2026 2025 2026 2025
Net sales $ 210,933 $ 203,121 $ 407,641 $ 396,767
Cost of sales 61,226 63,588 118,388 135,615
Gross profit 149,707 139,533 289,253 261,152
Sales, general, and administrative 138,030 136,493 272,941 269,474
Research and development 15,944 15,934 31,264 35,700
Acquisition-related amortization, impairment, and remeasurement 3,867 3,109 7,618 20,854
Operating loss (8,134 ) (16,003 ) (22,570 ) (64,876 )
Interest expense, net (6,085 ) (3,950 ) (11,749 ) (8,456 )
Other income (expense), net (778 ) 5,730 (1,512 ) 6,976
Loss before income taxes (14,997 ) (14,223 ) (35,831 ) (66,356 )
Income tax (expense) benefit (801 ) 142 (875 ) (819 )
Net loss $ (15,798 ) $ (14,081 ) $ (36,706 ) $ (67,175 )
Net loss per common share:
Basic $ (0.39 ) $ (0.36 ) $ (0.90 ) $ (1.71 )
Diluted (0.39 ) (0.36 ) (0.90 ) (1.71 )
Weighted average number of common shares (in millions):
Basic 40.9 39.5 40.7 39.3
Diluted 40.9 39.5 40.7 39.3
ORTHOFIX MEDICAL INC.Condensed Consolidated Balance Sheets
(U.S. Dollars, in thousands, except par value data) June 30, 2026 December 31, 2025
(Unaudited)
Assets
Current assets
Cash and cash equivalents $ 103,810 $ 82,025
Restricted Cash 595 3,090
Accounts receivable, net of allowances of $10,563 and $8,308, respectively 135,818 135,746
Inventories 184,475 172,319
Prepaid expenses and other current assets 21,434 23,667
Total current assets 446,132 416,847
Property, plant, and equipment, net 130,757 129,399
Intangible assets, net 65,972 72,765
Goodwill 194,934 194,934
Other long-term assets 35,225 36,702
Total assets $ 873,020 $ 850,647
Liabilities and shareholders’ equity
Current liabilities
Accounts payable $ 63,531 $ 58,392
Current portion of finance lease liability 125 837
Other current liabilities 93,354 111,253
Total current liabilities 157,010 170,482
Long-term debt 221,591 157,391
Long-term portion of finance lease liability 12,903 17,060
Other long-term liabilities 52,336 55,677
Total liabilities 443,840 400,610
Contingencies
Shareholders’ equity
Common shares $0.10 par value; 100,000 shares authorized; 40,730 and 39,834 issued and outstanding as of June 30, 2026, and December 31, 2025, respectively 4,073 3,983
Additional paid-in capital 830,423 813,769
Accumulated deficit (405,039 ) (368,333 )
Accumulated other comprehensive income (loss) (277 ) 618
Total shareholders’ equity 429,180 450,037
Total liabilities and shareholders’ equity $ 873,020 $ 850,647

**ORTHOFIX MEDICAL INC.
**Non-GAAP Financial Measures

The following tables present reconciliations of various financial measures calculated in accordance with U.S. generally accepted accounting principles (“GAAP”), to various non-GAAP financial measures that exclude (or in the case of free cash flow, include) items specified in the tables. The GAAP measures shown in the tables below represent the most comparable GAAP measure to the applicable non-GAAP measure(s) shown in the table. For further information regarding the nature of these exclusions, why the Company believes that these non-GAAP financial measures provide useful information to investors, the specific manner in which management uses these measures, and some of the limitations associated with the use of these measures, please refer to the Company’s current report on Form 8-K regarding this press release filed today with the SEC available on the SEC’s website at www.sec.gov and on the “Investors” page of the Company’s website at www.orthofix.com .

The Company’s non-GAAP financial measures for the three and six months ended June 30, 2026, and 2025, have been adjusted to eliminate the financial effects of the Company’s decision to discontinue its M6 product lines.

Adjusted Gross Profit and Adjusted Gross Margin
Three Months Ended June 30, Six Months Ended June 30,
(Unaudited, U.S. Dollars, in thousands) 2026 2025 2026 2025
Gross profit $ 149,707 $ 139,533 $ 289,253 $ 261,152
Share-based compensation and long-term incentive plan expense 462 467 793 929
SeaSpine merger-related costs 225 4,341 (303 ) 4,941
Restructuring costs and impairments related to M6 product lines 217 2,791 (220 ) 13,710
Gross profit attributable to M6 product line operations (53 ) (1,639 ) (295 ) (2,545 )
Strategic investments — 43 — 56
Amortization/depreciation of acquired long-lived assets 108 351 285 664
Employee transition costs 593 — 593 —
Adjusted gross profit $ 151,259 $ 145,887 $ 290,106 $ 278,907
Adjusted gross margin as a percentage of reported net sales 71.7 % 71.8 % 71.2 % 70.3 %
Adjusted gross margin as a percentage of pro forma net sales 71.7 % 72.7 % 71.2 % 71.5 %
Adjusted EBITDA
Three Months Ended June 30, Six Months Ended June 30,
(Unaudited, U.S. Dollars, in thousands) 2026 2025 2026 2025
Net loss $ (15,798 ) $ (14,081 ) $ (36,706 ) $ (67,175 )
Income tax expense (benefit) 801 (141 ) 875 819
Interest expense, net 6,085 3,950 11,749 8,456
Depreciation and amortization 13,273 16,871 26,766 51,302
Share-based compensation and long-term incentive plan expense 7,945 7,824 14,583 14,293
Foreign exchange impact 746 (2,751 ) 1,646 (3,795 )
SeaSpine merger-related costs 572 4,886 503 6,017
Restructuring costs and impairments related to M6 product lines 217 3,651 (220 ) 13,531
Operating losses attributable to M6 product lines 868 (297 ) 1,558 1,949
Strategic investments 634 353 1,584 3,867
Acquisition-related fair value adjustments 868 (763 ) 1,618 (1,373 )
Interest and loss on investments — (31 ) (16 ) (31 )
Litigation and investigation costs 2,185 4,029 5,101 7,071
Employee retention credit — (2,854 ) (951 ) (2,854 )
Employee transition costs 1,742 — 1,742 —
Adjusted EBITDA $ 20,138 $ 20,646 $ 29,832 $ 32,077
Adjusted EBITDA as a percentage of reported net sales 9.5 % 10.2 % 7.3 % 8.1 %
Adjusted EBITDA as a percentage of pro forma net sales 9.6 % 10.3 % 7.3 % 8.2 %
Adjusted Net Income (Loss)
Three Months Ended June 30, Six Months Ended June 30,
(Unaudited, U.S. Dollars, in thousands) 2026 2025 2026 2025
Net loss $ (15,798 ) $ (14,081 ) $ (36,706 ) $ (67,175 )
Share-based compensation and long-term incentive plan expense 7,945 7,824 14,583 14,293
Foreign exchange impact 746 (2,751 ) 1,646 (3,795 )
SeaSpine merger-related costs 574 7,786 591 9,260
Restructuring costs and impairments related to M6 product lines 176 4,257 (448 ) 34,461
Operating losses attributable to M6 product lines 1,006 (766 ) 1,922 1,922
Strategic investments 637 364 1,590 3,907
Acquisition-related fair value adjustments 868 (761 ) 1,618 (1,371 )
Amortization/depreciation of acquired long-lived assets 3,107 4,221 6,285 8,853
Litigation and investigation costs 2,185 4,029 5,101 7,071
Interest and loss on investments — (31 ) (16 ) (31 )
Employee retention credit — (3,616 ) (1,135 ) (3,616 )
Employee transition costs 1,742 — 1,742 —
Long-term income tax rate adjustment (316 ) (1,915 ) 1,534 (468 )
Adjusted net income (loss) $ 2,872 $ 4,560 $ (1,693 ) $ 3,311
Cash Flow and Free Cash Flow
Six Months Ended June 30,
(Unaudited, U.S. Dollars, in thousands) 2026 2025
Net cash used in operating activities $ (23,834 ) $ (6,752 )
Net cash used in investing activities (23,162 ) (13,833 )
Net cash provided by financing activities 66,421 1,989
Effect of exchange rate changes on cash (135 ) 1,547
Net change in cash and cash equivalents $ 19,290 $ (17,049 )
Six Months Ended June 30,
(Unaudited, U.S. Dollars, in thousands) 2026 2025
Net cash used in operating activities $ (23,834 ) $ (6,752 )
Capital expenditures (23,308 ) (13,845 )
Free cash flow $ (47,142 ) $ (20,597 )
Reconciliation of Non-GAAP Financial Measures to Reported Operating Expenses
Three Months Ended June 30, Six Months Ended June 30,
(Unaudited, U.S. Dollars, in thousands) 2026 2025 2026 2025
Sales, general, and administrative $ 138,030 $ 136,493 $ 272,941 $ 269,474
Reconciling items impacting sales, general, and administrative:
SeaSpine merger-related costs (270 ) (3,384 ) (756 ) (4,142 )
Restructuring costs and impairments related to M6 product lines 41 (1,393 ) 228 (4,729 )
Sales, general, and administrative expense attributable to M6 product lines (636 ) (243 ) (1,685 ) (2,631 )
Strategic investments (633 ) (194 ) (1,581 ) (1,741 )
Amortization/depreciation of acquired long-lived assets — — — (60 )
Litigation and investigation costs (2,185 ) (3,579 ) (5,101 ) (6,621 )
Employee transition costs (1,148 ) — (1,148 ) —
Sales, general, and administrative expense, as adjusted $ 133,199 $ 127,700 $ 262,898 $ 249,550
As a percentage of reported net sales 63.1 % 62.9 % 64.5 % 62.9 %
As a percentage of pro forma net sales 63.2 % 63.6 % 64.5 % 64.0 %
Three Months Ended June 30, Six Months Ended June 30,
(Unaudited, U.S. Dollars, in thousands) 2026 2025 2026 2025
Research and development expense, as reported $ 15,944 $ 15,934 $ 31,264 $ 35,700
Reconciling items impacting research and development:
SeaSpine merger-related costs (80 ) (62 ) (139 ) (178 )
Restructuring costs and impairments related to M6 product lines — (77 ) — (1,929 )
Research and development expense attributable to M6 product lines (413 ) (602 ) (659 ) (1,794 )
Strategic investments (3 ) (127 ) (8 ) (2,110 )
Litigation and investigation costs — (450 ) — (450 )
Research and development expense, as adjusted $ 15,448 $ 14,616 $ 30,458 $ 29,239
As a percentage of reported net sales 7.3 % 7.2 % 7.5 % 7.4 %
As a percentage of pro forma net sales 7.3 % 7.3 % 7.5 % 7.5 %
Reconciliations of Non-GAAP Financial Measures to Reported Non-Operating (Income) Expense
Three Months Ended June 30, Six Months Ended June 30,
(Unaudited, U.S. Dollars, in thousands) 2026 2025 2026 2025
Non-operating (income) expense $ 6,863 $ (1,780 ) $ 13,261 $ 1,480
Reconciling items impacting non-operating expense:
Restructuring costs and impairments related to M6 product lines — 3 — 3
Losses (income) attributable to M6 product lines (12 ) (26 ) 126 (41 )
Foreign exchange impact (746 ) 2,751 (1,646 ) 3,795
Interest and loss on investments — 31 16 31
Employee retention credit — 3,617 1,135 3,617
Non-operating expense, as adjusted $ 6,105 $ 4,596 $ 12,892 $ 8,885
As a percentage of reported net sales 2.9 % 2.3 % 3.2 % 2.2 %
As a percentage of pro forma net sales 2.9 % 2.3 % 3.2 % 2.3 %

**Company Contact
**
Investors and Media
Julie Dewey, IRC
Chief Investor Relations & Communications Officer
[email protected]

+1 209.613.6945

Source: Orthofix Medical Inc.

View All News

Investor Email Alerts

Personal Information.

Email Address *Required Email Address is required. Email Address is invalid.

Investor Alert Options *

  • News
  • Quarterly Reports
  • Annual Reports
  • SEC Filings
  • End of Day Stock Quote
  • Events & Presentations

Investor Alert Options is required.

The captcha test has failed. Please try again.

Submit

Unsubscribe

IR Contact

Julie Dewey

[email protected]

[email protected]

Quick Links

Company Name, Logo

                               


The materials on this site are for your general educational information only. Information you read on this website cannot replace the relationship that you have with your healthcare professional. We do not practice medicine or provide medical services as a part of this website. You should always talk to your healthcare professional for diagnosis and treatment.

© 2026 Orthofix Medical Inc. - All rights reserved

Powered By Q4 Inc. 5.190.1.9 (opens in new window)

Prompts

Orthofix Medical Inc. (ticker OFIX), listed in United States.

Company History

Date Change Detail
Aug 1, 2018 Renamed ORTHOFIX INTERNATIONAL N V → ORTHOFIX MEDICAL INC.

ETFs Holding Orthofix Medical Inc.

ETF Weight in ETF Shares Market value As of
BSVO 0.03% 94,465 $ 630K Nov 18, 2026
AVSC 0.02% 77,886 $ 529.625K Nov 16, 2026
DFAS 0.00% 215,527 $ 1.496M Nov 12, 2026
DXUV 0.00% 22,634 $ 157.08K Nov 12, 2026
DFAT 0.00% 42,249 $ 293.208K Nov 12, 2026
DFSV 0.00% 36,357 $ 252.318K Nov 12, 2026
DFAC 0.00% 100,330 $ 696.29K Nov 12, 2026
DFAU 0.00% 11,512 $ 79.893K Nov 12, 2026
DCOR 0.00% 5,000 $ 34.7K Nov 12, 2026
EBI 0.00% 1 $ 9.39 Aug 31, 2026
AVUS 0.00% 5,334 $ 36.271K Nov 16, 2026